Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, has launched an authorized generic of Omeprazole 40 mg capsules in the United States under an agreement with AstraZeneca Pharmaceuticals.

The drug is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome.

Omeprazole is the generic name of Prilosec. The most common side effects of Prilosec are headache, diarrhea and abdominal pain.  

Prilosec 40 mg had sales in the U.S. market of $204.2 million (IMS: March 2008 MAT).